Percentage of activated cytotoxic T-lymphocytes in anaplastic large cell lymphoma and Hodgkin's disease: An independent biological prognostic marker

Leukemia

Volumn 15, Issue 3, 2001, Pages 458-464

  Ten Berge, R L ^a   Oudejans, J J ^a   Dukers, D F ^a   Meijer, J W R ^b   Ossenkoppele, G J ^a   Meijer, C J L M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RIJNSTATE HOSPITAL   (Netherlands)

Author keywords

Activated CTLs; ALK negative ALCL; HD; Prognosis

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BIOLOGICAL MARKER; CHLORMETHINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANZYME B; MONOCLONAL ANTIBODY; PREDNISONE; PROCARBAZINE; VINCRISTINE; VINCRISTINE SULFATE;

ADOLESCENT; ADULT; AGE; AGED; ANAPLASTIC CARCINOMA; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; FEMALE; HISTOLOGY; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PARAMETER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ASSAY; SENSITIVITY AND SPECIFICITY; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; TUMOR BIOPSY; VIDEORECORDING;

EID: 0035084021     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402045     Document Type: Article

References (60)

1. A revised European-American classification of lymphoid neoplasms: A proposal from the International lymphoma study group
2. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma
3. Anaplastic large cell lymphomas expressing the novel chimeric protein p80 NPM/ALK: A distinct clinicopathologic entity
4. Adverse effects of activated cytotoxic T-lymphocytes on the clinical outcome of nodal anaplastic large cell lymphoma
5. ALK-positive lymphoma: Clinicopathological findings and outcome
6. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma
7. ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination
8. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1
9. High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease: Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, immunostaining
10. Amplification of genomic DNA demonstrates the presence of the t(2;5)(p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis
11. + primary cutaneous lymphoproliferative disorders and Hodgkin's disease
12. Reverse transcriptase polymerase chain reaction for the Ki-1 anaplastic large cell lymphoma-associated t(2;5) translocation in Hodgkin's disease
13. Hodgkin's disease
14. Principles of chemotherapy for lymphomas
15. A predictive model for aggressive non-Hodgkin's lymphoma
16. Activated cytotoxic T cells as prognostic marker in Hodgkin's disease
17. World Health Organization of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the clinical advisory committee meeting-airlie house, Virginia, November 1997
18. ALK expression defines a distinct group of T/Null lymphomas ('ALK lymphomas') with a wide morphological spectrum
19. ALK-positive lymphoma: A single disease with a broad spectrum of morphology
20. Production and characterization of monoclonal antibodies raised against recombinant human granzymes A and B and showing cross reactions with the natural proteins
21. Localization and identification of granzymes A and B expressing cells in normal human lymphoid tissue and peripheral blood
22. Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin rearrangements and appear to be derived from B cells at various stages of development
23. Hodgkin's disease with monoclonal and polyclonal populations of Reed-Sternberg cells
24. The origin of Hodgkin and Reed-Sternberg cells in Hodgkin's disease
25. Anaplastic large cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules
26. Genotypic analysis of large-cell lymphomas which express the Ki-1 antigen
27. Immunoglobulin and T-cell receptor gene rearrangements in Hodgkin's disease and Ki-1 positive anaplastic large cell lymphoma: Dissociation between phenotype and genotype
28. Rare occurrence of classical Hodgkin's disease as a T cell lymphoma
29. Detection of clonal T-cell receptor gamma-chain gene rearrangements in Reed-Sternberg cells of classic Hodgkin disease
30. Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large cell lymphomas. Diagnostic value in so-called malignant histiocytosis
31. Hodgkin's disease and CD30-positive anaplastic large cell lymphomas - A continuous spectrum of malignant disorders: A quantitative morphometric and immunologic study
32. Immunophenotype of Reed-Sternberg cells
33. +): Results of a prospective clinicopathologic study of 69 cases
34. Human lymphoid cells express epithelial membrane antigen. Implications for the diagnosis of human neoplasms
35. Monoclonal antibodies in the diagnosis of Hodgkin's disease: The search for a rational panel
36. Epithelial membrane antigen in hematolymphoid neoplasms: A review
37. Anaplastic large cell lymphoma - A distinct molecular pathologic entity: A reappraisal with special reference to p80 (NPM/ALK) expression
38. CD30-positive anaplastic large cell lymphoma in childhood - Expression of p80 (NPM/ALK) and absence of Epstein-Barr virus
39. + anaplastic large cell lymphomas (ALCL): Correlation with morphology, immunophenotype, ultrastructure, and clinical features
40. A cytotoxic phenotype does not predict clinical outcome in anaplastic large cell lymphoma
41. Cytotoxic cell antigen expression in anaplastic large cell lymphomas of T- and null-cell type and Hodgkin's disease: Evidence for a distinct cellular origin
42. Granzyme B expression in Reed-Sternberg cells of Hodgkin's disease
43. Epstein-Barr virus in Hodgkin's disease
44. Demonstration of monoclonal EBV genomes in Hodgkin's disease and Ki-1 positive anaplastic large cell lymphoma by combined Southern blot and in situ hybridization
45. Epstein-Barr virus DNA and latent gene products in Ki-1 (CD30) positive anaplastic large cell lymphomas
46. High incidence of Epstein-Barr virus detection in Hodgkin's disease and absence of detection in anaplastic large cell lymphoma in children
47. High incidence of EBV genome in CD30-positive non-Hodgkin's lymphomas
48. Epstein-Barr virus is present in neoplastic cytotoxic T cells in extranodal, and predominantly in B cells in nodal T non-Hodgkin lymphomas
49. Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV(+) Hodgkin's disease
50. Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: Analysis of the HLA class I processing pathway and the effects of interleukin-10 on Epstein-Barr virus-specific cytotoxic T-cell recognition
51. Bcl-2 family. Regulators of cell death
52. Molecular thanatopsis: A discourse on the bcl2 family and cell death
53. Regulation of Fas (APO-1/CD95)- and perforin-mediated lytic pathways of primary cytotoxic T lymphocytes by the protooncogene bcl-2
54. Involvement of the CD95 (APO/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells
55. Low p53 and high bcl-2 expression in Reed-Sternberg cells predicts poor clinical outcome of Hodgkin's disease: Involvement of apoptosis resistance
56. IL-10 inhibits human T-cell proliferation and IL-2 production
57. Interleukin 10 treatment protects target cells from tumour- and allospecific cytotoxic T-cells and downregulates HLA class I expression
58. Quantitative immunohistochemical analysis of cytokine profiles in Epstein-Barr virus positive and negative cases of Hodgkin's disease
59. + T lymphocytes
60. Human interleukin-10 expression in T/natural killer-cell lymphomas. Association with anaplastic large cell lymphomas and nasal natural killer-cell lymphomas